Mesoblast (MESO) Accounts Payables (2015 - 2025)
Mesoblast (MESO) posted quarterly Accounts Payables of $33.6 million for Q4 2025, up 183.1% year-on-year from $11.9 million in Q4 2024, and up 75.96% on a QoQ basis from $19.1 million in Q2 2025.
Mesoblast (MESO) Accounts Payables (2015 - 2025) Analysis & Trends
Mesoblast (MESO) has reported Accounts Payables for 11 consecutive years, with $33.6 million the latest figure, recorded in Q4 2025.
- Quarterly Accounts Payables rose 183.1% year-over-year to $33.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $33.6 million (up 183.1% YoY) and the FY2025 annual result came in at $19.1 million, up 169.9% from the prior year.
- Accounts Payables improved to $33.6 million in Q4 2025 per MESO's latest filing, from $19.1 million in the prior quarter.
- Over the last five years, Accounts Payables for MESO reached as high as $33.6 million in Q4 2025 and fell as low as $7.1 million in Q2 2024.
- A 5-year average of $19.1 million and a median of $19.6 million in 2021 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2024 — Accounts Payables plunged 64.9% — and 2025, when it surged 183.1%.
- Year by year, Accounts Payables stood at $20.9 million in 2021, then advanced by 9.91% to $23.0 million in 2022, then slumped by 53.2% to $10.8 million in 2023, then gained by 10.22% to $11.9 million in 2024, then jumped by 183.1% to $33.6 million in 2025.
- According to Business Quant data, Accounts Payables over the past three periods registered $33.6 million, $19.1 million, and $11.9 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 5.74 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 10.62 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 423.55 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 694,346.76 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 489.30 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.03 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.52 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 80.54 Mn |
| 10 | Mesoblast | 2.08 Bn | 1.95 Bn | - | 33.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 33.58 Mn |
| Jun 30, 2025 | 19.08 Mn |
| Dec 31, 2024 | 11.86 Mn |
| Jun 30, 2024 | 7.07 Mn |
| Dec 31, 2023 | 10.76 Mn |
| Jun 30, 2023 | 20.15 Mn |
| Mar 31, 2023 | 20.97 Mn |
| Dec 31, 2022 | 22.99 Mn |
| Sep 30, 2022 | 17.66 Mn |
| Jun 30, 2022 | 23.08 Mn |
| Mar 31, 2022 | 18.98 Mn |
| Dec 31, 2021 | 20.92 Mn |
| Sep 30, 2021 | 16.26 Mn |
| Jun 30, 2021 | 19.60 Mn |
| Mar 31, 2021 | 24.28 Mn |
| Dec 31, 2020 | 28.61 Mn |
| Sep 30, 2020 | 27.60 Mn |
| Jun 30, 2020 | 24.97 Mn |
| Mar 31, 2020 | 19.48 Mn |
| Dec 31, 2019 | 19.24 Mn |